https://clinicaltrials.gov/ct2/show/NCT03482011?type=Intr&cond=Psoriasis&lupd_s=04%2F11%2F2019&lupd_d=14
Condition : Psoriasis
Interventions : Drug: Mirikizumab; Drug: Placebo
Sponsor : Eli Lilly and Company
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03482011
Thu, 29 Mar 2018 12:00:00 EDT
Last Update Posted: 04/25/19 07:39AM
